The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index; 65 of the 134 sources its claims cite were checked for support.
Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis
Open accessAbstract
Serum tryptase level has long been used as a biomarker in clinical practice to suspect mast-cell associated disorders. Basal serum tryptase (BST) above 20 ng/ml represents a minor criterion according to WHO and ICC for the diagnosis of systemic mastocytosis (SM) although normal BST value does not exclude the diagnosis. Nevertheless, BST can be elevated also due to non-SM related diseases as well as hereditary alpha-tryptasemia (H α T), an autosomal dominant germline condition that consists in the increase of the number of copies of the TPSAB1 gene encoding the alpha isoform of tryptase. The prevalence of H α T is estimated at around 5% of the general population. Individuals with H α T genotype can be asymptomatic; however, some of them can experience a range of symptoms with a large variability in type and severity, posing a problem of differential diagnosis with SM. The increasing awareness on a potentially SM underlying diverse clinical manifestations has led to excessive BST testing by several specialists, a trend that risks over interpreting some borderline results. The interpretation of elevated BST should thus be carefully appraised in specific clinical contexts on individual basis. This review is intended to examine the existing literature on this topic and offers a guide for interpreting the BST to rationalize the application of invasive diagnostic procedures.
Overview
CoChat Summary
TL;DR
This review argues that basal serum tryptase (BST) must be interpreted in clinical context because hereditary alpha-tryptasemia (HαT) and other conditions can elevate BST, confounding systemic mastocytosis (SM) diagnosis. It proposes using REMA score, peripheral blood KIT D816V testing, and HαT genotyping to rationalize invasive diagnostics, while noting BST >20 ng/ml is a minor WHO/ICC criterion but normal BST does not exclude SM.
Key findings
- BST normal values have been reported as 1–11.5 ng/ml, while ECNM/AIM proposed a normal range of 1–15 ng/ml including asymptomatic HαT individuals; BST >20 ng/ml is a minor diagnostic criterion for SM and >200 ng/ml is a B-finding for smoldering SM. HαT prevalence is estimated at around 5% in the general population and up to 12%–20% in SM patients, with each extra TPSAB1 copy adding approximately 9–10 ng/ml to BST.
- HαT can confound BST interpretation; several empirical correction formulae exist (Valent, Lyons, Chollet, Chovanec), but all are still to be validated prospectively. HαT may act as a clinical amplifier in SM: severe episodes were twice more frequent in individuals with both SM and HαT than in those with SM without HαT.
- KIT D816V is present in over 90% of SM cases. Peripheral blood testing shows a discordance rate of 5%–10% versus bone marrow; in a PIONEER post hoc analysis, central ddPCR detected KIT D816V in 37/39 (95%) PB samples versus 11/39 (28%) by NGS and 30/39 (80%) locally. Negative predictive value was approximately 40% in patients with BST levels between 5 and 30 ng/ml.
- Scoring systems include REMA, NICAS, Fuchs, and OSTEO. For patients without mastocytosis in the skin, ECNM recommends bone marrow biopsy when BST is greater than 25–30 ng/ml, REMA score is ≥2, or KIT D816V is detected in PB; in low REMA score (<2), no clear mediator-related symptoms, and elevated BST alone, initial PB KIT D816V and HαT testing are suggested, with SM reasonably excluded if KIT is negative and HαT genotype is confirmed.
Methods
- Narrative review of existing literature on BST interpretation in suspected SM, HαT, KIT D816V testing, and scoring models; no primary patient cohort or systematic search is described.
- Synthesizes diagnostic criteria from the 2022 ICC and WHO 5th edition, HαT genetics, tryptase thresholds, KIT assay performance, and scoring systems including REMA, NICAS, Fuchs, and OSTEO.
- Proposes a basic algorithm for suspected SM based on REMA score, typical skin lesions, BST >15 ng/ml, PB KIT D816V testing, and HαT testing.
Limitations
- Stated: all attempts to adjust BST for HαT are empirical and still to be validated prospectively; correlations between HαT and severe anaphylaxis are debated and need confirmation in larger datasets; urinary mediator findings require further validation.
- Stated: despite improved KIT variant detection in PB, major limitations remain, and patients with very low disease burden classified as MMAS/cMCAS show the greatest BM/PB KIT discrepancies and remain a grey zone.
- Evident: as a narrative review, no systematic search or quantitative synthesis is reported, and recommendations rely on cited literature and expert consensus rather than new primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
49 Valid · 3 Not valid · 26 Not checked · 12 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“severe episodes were twice more frequent in individuals with both SM and HαT than in those with SM but without HαT (17, 18).”
§ Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis > Hereditary alpha tryptasemia and mastocytosis: a clinical interaction?
What the sources say
- Not checked — no full text of the sourcecites [17] Lyons, 2021, Heritable risk for severe anaphylaxis associated with increased α-tryptase–encoding germline copy number at TPSAB1, J Allergy Clin Immunol source
- Partly supportedcites [18] Li, 2023, Review and updates on systemic mastocytosis and related entities, Cancers sourceExperimental — accuracy not yet measured
Section 2.2 (page not available) says concurrent HαT predisposes patients with mastocytosis to severe mediator-related symptoms. It does not report that severe episodes are twice as frequent in patients with both SM and HαT as in patients with SM alone. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Basal serum tryptase (BST) above 20 ng/ml represents a minor criterion according to WHO and ICC for the diagnosis of systemic mastocytosis (SM)”
- Also stated in: § Tryptase in suspected SM: the interference by HαT · plain
“BST is used as one of the main biomarkers in the suspicion of SM and represents a minor criterion for diagnosis when its value exceeds 20 ng/ml (7, 8).”
§ Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis > Abstract
What the sources say
- Not checked — no full text of the sourcecites [7] Arber, 2022, International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data, Blood source
- Partly supportedcites [8] Khoury, 2022, The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms, Leukemia sourceExperimental — accuracy not yet measured
The Mastocytosis section states that basal serum tryptase >20 ng/ml is a minor criterion for systemic mastocytosis in the WHO classification, with adjustment in cases of hereditary alpha-tryptasaemia. This WHO paper does not establish the claim about ICC criteria. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Tryptase in suspected SM: the interference by HαT · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“although normal BST value does not exclude the diagnosis”
- Also stated in: § Analysis of KIT D816V variant in peripheral blood · plain
“a normal BST value does not exclude a diagnosis of SM, as evidenced by patients with BMM, who often present with normal BST levels (50–52).”
§ Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis > Abstract
What the sources say
- Not checked — no full text of the sourcecites [50] Álvarez-Twose, 2014, Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM, J Allergy Clin Immunol source
- Supportedcites [51] Zanotti, 2022, Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis, Leukemia source
The Discussion proposes diagnosing bone marrow mastocytosis, a variant of systemic mastocytosis, using SM criteria and a serum tryptase level below 125 ng/mL. That proposed criterion does not require elevated tryptase, so a normal value would not by itself exclude the diagnosis. (LLM, conf=0.84)
- Supportedcites [52] Zanotti, 2011, Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis, Haematologica source
The Abstract states that bone marrow mastocytosis, a subvariant of indolent systemic mastocytosis, can occur even with normal tryptase levels. It also lists elevated serum tryptase as only one of several possible minor diagnostic criteria for systemic mastocytosis. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Analysis of KIT D816V variant in peripheral blood · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing knowledge of hereditary alpha-tryptasemia (HαT), a germline condition causing increase in BST with not fully elucidated clinical consequences (4–6).”
§ Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis > Introduction
What the sources say
- Supportedcites [4] Lyons, 2018, Hereditary alpha tryptasemia: genotyping and associated clinical features, Immunol Allergy Clin North Am source
The Future Considerations / Summary section describes HαT as an inherited genetic trait caused by increased TPSAB1 copies and says affected individuals have elevated BST. It also states that questions remain about the associated clinical phenotypes and whether the trait causes or modifies them. (LLM, conf=0.94)
- Partly supportedcites [5] Lyons, 2021, Inherited and acquired determinants of serum tryptase levels in humans, Ann Allergy Asthma Immunol sourceExperimental — accuracy not yet measured
The section “Hereditary Alpha-Tryptasemia: the Most Common Cause for BST Elevation” (page not provided) identifies HαT as an autosomal dominant genetic trait caused by increased TPSAB1 copy number and links it to higher BST. The paper describes some associated clinical findings, but the passages reviewed do not say that HαT’s clinical consequences remain incompletely elucidated. (LLM, conf=0.83)
- Supportedcites [6] Beyens, 2023, Diagnostic significance of tryptase for suspected mast cell disorders, Diagnostics source
The Discussion describes HαT as an inherited genetic trait and a common cause of elevated baseline serum tryptase. It says more research is needed on its pathological effects and notes debate and conflicting findings about its clinical presentation. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“hereditary alpha-tryptasemia (HαT), an autosomal dominant germline condition that consists in the increase of the number of copies of the TPSAB1 gene encoding the alpha isoform of tryptase”
- Also stated in: § Hereditary alpha tryptasemia and mastocytosis: a clinical interaction? · plain
“HαT, an autosomal dominant condition resulting from the multiplication of the TPSAB1 gene (Figure 1) encoding the alpha isoform of tryptase”
§ Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis > Abstract
What the sources say
- Supportedcites [4] Lyons, 2018, Hereditary alpha tryptasemia: genotyping and associated clinical features, Immunol Allergy Clin North Am source
The Future Considerations / Summary section states that hereditary alpha tryptasemia is caused by increased copies of TPSAB1 encoding alpha-tryptase and is inherited in an autosomal dominant manner. The paper also identifies the extra copies as germline copies. (LLM, conf=0.95)
- Not checked — no full text of the sourcecites [11] Lyons, 2016, Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number, Nat Genet source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Hereditary alpha tryptasemia and mastocytosis: a clinical interaction? · plain
19 more claims · 8 with their cited sources checked
Create a free account to see all 90 claims and to verify the 5 references still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 56
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“37/39 (95%) of PB samples compared with 11/39 (28%) analyzed by NGS and 30/39 (80%) of PB samples analyzed locally”
§ Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis > Analysis of KIT D816V variant in peripheral blood
Reported 80 · recomputed 76.923077
Citations
Cites
Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01613-1 · Cited by 4,274
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750
Valent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Brockow, K., Jofer, C., Behrendt, H., & Ring, J. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01569.x · Cited by 523
Schwartz, L. B., Yunginger, J. W., Miller, J., Bokhari, R., & Dull, D. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114051 · Cited by 456
Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool
Huggett, J. F., Cowen, S., & Foy, C. A. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.221366 · Cited by 444
Valent, P., Spanblochl, E., Sperr, W., Sillaber, C., Zsebo, K., Agis, H., Strobl, H., Geissler, K., Bettelheim, P., & Lechner, K. (1992) · Blood · doi:10.1182/blood.v80.9.2237.2237 · Cited by 439
Lyons, J. J., Yu, X., Hughes, J. D., Le, Q. T., Jamil, A., Bai, Y., Ho, N., Zhao, M., Liu, Y., O'Connell, M. P., et al. (2016) · Nature Genetics · doi:10.1038/ng.3696 · Cited by 394
Cited by
Role of Mast Cells and Their Mediators in Chronic Kidney Diseases
Tziastoudi, M., Cholevas, C., Eleftheriadis, T., Stefanidis, I., & Theoharides, T. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209981 · Cited by 8
“Recent publications increased the cut off limit to 20 ng/mL [100,101].”
Kapçay, O., Şahin, F. D., & Kılıç, M. (2026) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.1963920
Metadata
- Authors
- Crupi, F., Caroprese, J., & Mannelli, F.
- Affiliations
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Corresponding author
- Mannelli, Francesco
- Venue
- Frontiers in Allergy
- Publisher
- Frontiers Media SA
- Published
- 2025-05-12
- Volume
- 6
- Pages
- 1592001-1592001
- ISSN
- 2673-6101 (ISSN-L)
- PMC
- PMC12104249
- OpenAlex
- W4410282155
- Cited by
- 2
- References
- 72
- Citations by year
- 2026: 1 · 2025: 1
- FWCI
- 0.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Allergy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- systemic mastocytosis, hereditary alpha-tryptasemia, differential diagnosis, diagnostic criteria, overuse of diagnostic testing, mast cell disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis. https://app.cochat.ai/papers/10.3389/falgy.2025.1592001
- The paper
- Crupi, F., Caroprese, J., & Mannelli, F. (2025). Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis. Frontiers in Allergy. https://doi.org/10.3389/falgy.2025.1592001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.